ARTICLE | Clinical News
RC-1291: Phase II started
July 25, 2005 7:00 AM UTC
Rejuvenon began a double-blind, placebo-controlled, U.S. Phase II trial in <100 patients. RC-1291 has Fast Track designation to treat cachexia and anorexia in cancer patients. ...